PMN Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 17.28
- P/S (TTM)
- 4016.22
- EV/EBITDA
- -1.74
Profitability & growth
- ROE (TTM)
- -522.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- -0.15
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About ProMIS Neurosciences Inc.
Company profileProMIS Neurosciences Inc. is a pioneering biotechnology company specializing in the development of innovative therapeutic solutions for neurodegenerative diseases, with a primary focus on Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Utilizing its proprietary protein engineering platform, ProMIS adeptly identifies and targets misfolded proteins associated with these debilitating disorders, promising novel treatments that prioritize enhanced safety and efficacy. The company boasts a robust pipeline of drug candidates at various stages of development, positioning ProMIS as a key…
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 1920 YONGE STREET, TORONTO, ON
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer